ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Enzyme-Linked Immunoabsorbant Assays (ELISA)"

  • Abstract Number: 130 • 2019 ACR/ARP Annual Meeting

    Is There Clinically Relevant Plasma Interference with ELISA Detection of APS Antibodies? Reproducibility of Serum and Plasma Testing in a Real-World Clinical Setting

    Michael Pham1, Giovanni Orsolini 2, Cynthia Crowson 3, Melissa Snyder 1, Rajiv Pruthi 4 and Kevin Moder 5, 1Mayo Clinic, Rochester, MN, 2University of Verona, Verona, Italy, 3Mayo Clinic Rochester, Rochester, 4Mayo Clinic, Rochester, 5Mayo Clinic Rochester, rochester, MN

    Background/Purpose: Traditionally in ELISA detection of APS antibodies, the use of serum is thought to be preferable over plasma according to international consensus bodies.  The…
  • Abstract Number: 491 • 2019 ACR/ARP Annual Meeting

    Diagnostic Performance of Anti-cyclic Citrullinated Peptide (CCP) 2 and CCP3.1 Assays in Early Rheumatoid Arthritis

    Daniela Sieghart1, Christian Konrad 2, Sascha Swiniarski 2, Helmuth Haslacher 3, Daniel Aletaha 4 and Günter Steiner 1, 1Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Vienna, Austria, Vienna, Austria, 2Thermo Fisher Scientific, Freiburg, Germany, Freiburg, Germany, 3Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria, Vienna, Austria, 4Medical University of Vienna, Vienna, Austria

    Background/Purpose: Anti-cyclic citrullinated peptide (CCP) antibodies are the most specific markers for rheumatoid arthritis (RA). Different generations of assays (CCP1-CCP3) have been developed which show…
  • Abstract Number: 661 • 2019 ACR/ARP Annual Meeting

    Association of Serum and Urine Levels of TWEAK, MCP-1 and NGAL with Disease Activity in Systemic Lupus Erythematosus

    SAFAK MIRIOGLU 1, SUZAN CINAR 2, Halil Yazici 3, Ahmet Gül 4, Lale Öcal 4, Murat Inanc 4 and Bahar Artim-Esen4, 1Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, ISTANBUL, Turkey, 2Istanbul University,Department of Immunology, Institute of Experimental Medicine, ISTANBUL, Turkey, 3Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Nephrology, Istanbul, Turkey, 4Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey

    Background/Purpose: TWEAK, MCP-1 and NGAL, mediators in pathogenesis of systemic lupus erythematosus (SLE), are proinflammatory cytokines/chemokines that are thought as potential biomarkers reflecting disease activity.…
  • Abstract Number: 2642 • 2019 ACR/ARP Annual Meeting

    ANCA Testing: Final Diagnoses in Cases with Positive Immunofluorescence and Negative ELISA

    ‪Gabriel Breuer‬‏1, Bashar Fteiha 1, Alon Benaya 1, Marwan Abu Sneineh‬‏ 1 and Gideon Nesher 1, 1Shaare Zedek Medical Center, Jerusalem, Yerushalayim, Israel

    Background/Purpose: With the widespread availability of anti-neutrophil cytoplasmic antibody (ANCA) testing, interpreting positive results has become increasingly challenging. In addition to ANCA Associated Vasculitis (AAV),…
  • Abstract Number: 596 • 2016 ACR/ARHP Annual Meeting

    Association Between Plasma Certolizumab Pegol Concentration and Improvement in Disease Activity in Rheumatoid Arthritis and Crohn’s Disease

    Gerrit Wolbink1,2, Philippe Goupille3, William Sandborn4, Hubert Marotte5, Denis Mulleman3, David Ternant3, Stéphane Paul5, Marc de Longueville6, Niels Vande Casteele4,7, Miren Zamacona6, Cathy O'Brien6, Tore K. Kvien8 and Arthur F. Kavanaugh9, 1Amsterdam Rheumatology Immunology Center (ARC), Reade, Amsterdam, Netherlands, 2Department of Immunopathology, Sanquin, Amsterdam, Netherlands, 3Université François-Rabelais, Tours, France, 4Division of Gastroenterology, UC San Diego School of Medicine, La Jolla, CA, 5Centre Hospitalier Universitaire de Saint-Étienne, Saint-Étienne, France, 6UCB Pharma, Brussels, Belgium, 7KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, 8Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 9Division of Rheumatology, Allergy & Immunology, UC San Diego School of Medicine, La Jolla, CA

    Background/Purpose: Anti-TNFs neutralize the TNF-mediated component of inflammatory diseases such as rheumatoid arthritis (RA) and Crohn’s disease (CD) to reduce disease activity. In this study,…
  • Abstract Number: 1073 • 2016 ACR/ARHP Annual Meeting

    Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking (APS ACTION) Clinical Database and Repository Analysis: The Comparison of Real World and Core Laboratory Antiphospholipid Antibody ELISA Results

    Savino Sciascia1, Rohan Willis2, Vittorio Pengo3, Steven Krilis4, Danieli Andrade5, Doruk Erkan6, Maria Laura Bertolaccini7 and On Behalf of APS ACTION .8, 1Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, 2Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, 3Azienda Ospedaliera of Padova, University of Padova, Padova, Italy, 4Department of Immunology, Allergy and Infectious Diseases, University of New South Wales, Sydney, Australia, 5Rheumatology, University of Sao Paulo, Sao Paulo, Brazil, 6Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, 7Academic Department of Vascular Surgery, King’s College London, London, United Kingdom, 8., New York, NY

    Background/Purpose: The APS ACTION International Clinical Database and Repository (“Registry”) was created to study the natural course of disease over 10 years in persistently aPL-positive…
  • Abstract Number: 2589 • 2016 ACR/ARHP Annual Meeting

    Comparison of Two Enzyme-Linked Immunosorbent Assays Used for Drug Concentration Monitoring in Psoriatic Arthritis Patients Treated with Certolizumab Pegol

    Stéphane Paul1, John Smeraglia2, Marc de Longueville2, Cathy O'Brien2 and Ermis Parussini3, 1Centre Hospitalier Universitaire de Saint-Étienne, Saint-Étienne, France, 2UCB Pharma, Brussels, Belgium, 3Theradiag, Croissy-Beaubourg, France

    Background/Purpose: Measurement of plasma anti-TNF concentration, in combination with the assessment of clinical outcomes, may be used to optimize dosing regimens for individual patients (pts).…
  • Abstract Number: 821 • 2015 ACR/ARHP Annual Meeting

    Elevated Serum Levels of Soluble CD146 in Patients with Systemic Sclerosis

    Kazunori Kato1, Tomoko Ito2, Naoto Tamura2, Sayuri Okuda1, Masakazu Matsushita2, Kurisu Tada2, Ken Yamaji2 and Yoshinari Takasaki2, 1Department of Biomedical Engineering, Toyo University, Saitama, Japan, 2Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan

    Background/Purpose: CD146 is a transmembrane glycoprotein belonging to Ig-superfamily. Human endothelial cells, activated fibroblasts and Th17 cells express CD146 that involved in angiogenesis, fibrosis and…
  • Abstract Number: 1258 • 2014 ACR/ARHP Annual Meeting

    Enzyme-Linked Immunosorbent Assays for Detection of Anti-Transcriptional Intermediary Factor-1 Gamma and Anti-Mi-2 Autoantibodies in Dermatomyositis: Utility and Crossreactivity

    Manabu Fujimoto1, Akihiro Murakami2, Shunsuke Kurei2, Akiko Kuwajima3, Yasuhiro Fujisawa1, Atsushi Kawakami4, Michiaki Mishima5, Shinji Sato6, Mariko Seishima7, Takafumi Suda8, Tsuneyo Mimori9, Kazuhiko Takehara10 and Masataka Kuwana11, 1Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, 2Medical & Biological Laboratories Co., Ltd, Nagaya, Japan, 3Medical & Biological Laboratories Co.,Ltd., Nagoya, Japan, 4Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 5Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Kyoto, Japan, 6Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan, 7Department of Dermatology, Gifu University Graduate School of Medicine, Gifu, Japan, 8Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan, 9Dept of Rheum & Clinical Immunology, Kyoto Univ Grad Schl of Med, Kyoto, Japan, 10Dermatology, Kanazawa University, Kanazawa, Japan, 11Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

    Background/Purpose Anti-transcriptional intermediary factor 1 (TIF-1) and anti-Mi-2 antibodies (Abs) are myositis-specific autoantibodies (MSA) selectively detected in dernatomyositis (DM) patients. Anti-TIF-1 Ab is frequently found…
  • Abstract Number: 648 • 2013 ACR/ARHP Annual Meeting

    A Possible Contribution of Inducible Costimulator to the Development of Skin Sclerosis and Interstitial Lung Disease in Systemic Sclerosis

    Koichi Yanaba1, Yoshihide Asano2 and Shinichi Sato2, 1Dermatology, The University of Tokyo, Tokyo, Japan, 2Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan

    Background/Purpose: Systemic sclerosis (SSc) is a heterogeneous disorder characterized by excessive fibrosis and microvascular damage of the skin and various internal organs. Cutaneous mononuclear cell…
  • Abstract Number: 26 • 2013 ACR/ARHP Annual Meeting

    Autoantibodies Directed Against Cell Surface Components In Autoimmune Disease Patients: Proposal Of a Novel ELISA For The Detection Of Anti-Endothelial Cell Antibodies

    Keiji Miura1, Ayako Kondo2, Kazuo Takahashi2, Daisuke Hirano2, Yoshiyuki Hiki3, Shunji Yoshida2, Yukio Yuzawa2 and Yoshikazu Kurosawa3, 1Institute for Comprehensive Medical Science, Fujita Health Universtiy, Toyoake, Japan, 2Fujita Health Universtiy School of Medicine, Toyoake, Japan, 3Fujita Health Universtiy, Toyoake, Japan

    Background/Purpose: Sera from patients with systemic vasculitis or inflammatory conditions have been reported to contain antibodies that bind to endothelial cells (EC), i.e., AECA (anti-endothelial…
  • Abstract Number: 1536 • 2012 ACR/ARHP Annual Meeting

    Clinical Features of Patients with Anti-Neutrophil Cytoplasmic Autoantibodies Targeting Native Myeloperoxidase Antigen

    Yuji Yamanishi1, Toshiko Ito-Ihara2, Shigeto Kobayashi3, Peter Y. Shane4, Gary S. Firestein5, Hiroshi Hashimoto6 and Kazuo Suzuki7, 1Division of Rheumatology, Hiroshima Rheumatology Clinic, Hiroshima, Japan, 2Department of Clinical Innovative Medicine, Translational Research Center, Kyoto University Hospital, Kyoto, Japan, 3Department of Internal Medicine, Juntendo University Koshigaya Hospital, Tokyo, Japan, 4Tokyo Medical and Dental University, Tokyo, Japan, 5Div of Rheumatology, UCSD School of Medicine, La Jolla, CA, 6Juntendo Tokyo Koto Geriatric Center, Tokyo, Japan, 7National Institute of Infectious Diseases, Tokyo, Japan

    Background/Purpose: ANCA is a useful diagnostic marker in systemic vasculitic disorders with small-vessel involvement, but depending on the particular test used the myeloperoxidase (MPO)-ANCA results…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.